Trial · NCT03123588
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) Control | Group A : Ruxolitinib and Anagrelide Placebo | 0 | proportion of participants | ||
| Proportion of Subjects Who Achieve Platelet and White Blood Cell (WBC) Control | Group B : Anagrelide and Ruxolitinib PLacebo | 0.17 | proportion of participants | ||
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Group A : Ruxolitinib and Anagrelide Placebo | 5 | participants | ||
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Group B : Anagrelide and Ruxolitinib PLacebo | 4 | participants | ||
| Proportion of Subjects Who Achieve Complete Remission or Partial Remission | Group A : Ruxolitinib and Anagrelide Placebo | 0 | proportion of participants | ||
| Proportion of Subjects Who Achieve Complete Remission or Partial Remission | Group B : Anagrelide and Ruxolitinib Placebo | 0.17 | proportion of participants | ||
| Time to Treatment Discontinuation | Group A : Ruxolitinib and Anagrelide Placebo | 261.2 | Standard Deviation 238.85 | Days | |
| Time to Treatment Discontinuation | Group B : Anagrelide and Ruxolitinib Placebo | 437.2 | Standard Deviation 183.99 | Days | |
| Duration of Response | Group B : Anagrelide and Ruxolitinib PLacebo | 442 | Days | ||
| Proportion of Subjects Who Achieve Reduction of Platelet Counts to < 600 × 10^9/L | Group A : Ruxolitinib and Anagrelide Placebo | 0 | Proportion of participants | ||
| Proportion of Subjects Who Achieve Reduction of Platelet Counts to < 600 × 10^9/L | Group B : Anagrelide and Ruxolitinib Placebo | 0.50 | Proportion of participants | ||
| Proportion of Subjects Who Achieve a Reduction of WBC Counts to < 10 × 109/L | Group A : Ruxolitinib and Anagrelide Placebo | 0 | Proportion of participants | ||
| Proportion of Subjects Who Achieve a Reduction of WBC Counts to < 10 × 109/L | Group B : Anagrelide and Ruxolitinib PLacebo | 0.33 | Proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03123588/results